Pasar al contenido principal

NEXT GENERATION OF NANOCONTAINERS FOR CANCER TREATMENT

PCI2025-163261

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Transferencia y Colaboración
Subprograma Subprograma Estatal para impulsar la Colaboración en y entre los Sectores Público y Privado
Convocatoria Proyectos Programación Conjunta Internacional
Año convocatoria 2025
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting toll-like receptors in the immunotherapy era: the chemistry behind TLR modulators

  • Mínguez-Toral, Marina
  • Fernández-Vasco, Gema
  • Furjun, Ameerah B.
  • Matamoros-Recio, Alejandra
  • Martín-Cámara, Olmo
  • Martín-Santamaría, Sonsoles
Toll-like receptors (TLRs) comprise a family of transmembrane pattern-recognition receptors that sense pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), thereby orchestrating innate immune responses. Over the past decade, TLRs have emerged as promising therapeutic targets for infectious, inflammatory, autoimmune, and oncological diseases. This review provides a comprehensive overview of TLR agonists and antagonists reported in the last ten years, highlighting an exceptional range of chemical classes, including peptides, nucleic acids, glycolipids, lipopeptides, and small molecules. We discuss the structural determinants underlying receptor selectivity, the design strategies enabling functional modulation, and the progress in preclinical and clinical development. We also address emerging trends, remaining challenges, and opportunities for the rational design of next-generation TLR modulators with improved selectivity and therapeutic potential., Funding from the Spanish Ministry of Science and Innovation (PID2020-113588RB-I00, PID2023-152271NB-I00, PRE2018-086249, PRE2021-097247, PREP2023-002126, and PCI2025-163261 MICIU/AEI/10.13039/501100011033/UE) and European Commission (ERA4Health Partnership NANOTECMEC 2024. Ref. “NextNano4Cancer” GA No. 101095426 of the EU Horizon Europe Research and Innovation Programme) are gratefully acknowledged., Peer reviewed